WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1793% more annual revenue ($56.58B vs $2.99B). NVS leads profitability with a 23.9% profit margin vs -10.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).

MMED

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 5.0

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

NVSSignificantly Overvalued (-52.0%)

Margin of Safety

-52.0%

Fair Value

$109.95

Current Price

$148.34

$38.39 premium

UndervaluedFair: $109.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$275.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

MMED4 concerns · Avg: 2.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
-10.7%1/10

Currently unprofitable

Operating MarginProfitability
-11.0%1/10

Operating margin of -11.0%

NVS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.562/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.

MMED is growing revenue faster at 15.0% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 38/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?